

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 9, 2004

Signature:

Linda Blake
(Linda Blake)

Docket No.: JJJ-P02-510
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Marc F. Charette

Application No.: 10/734472

Filed: December 12, 2003

Confirmation No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

For: METHODS AND COMPOSITIONS FOR
ENHANCING COGNITIVE FUNCTION
USING MORPHOGENIC PROTEINS

February 9, 2004

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Since this Information Disclosure Statement is filed within three months of the U.S. filing date, this IDS should be considered by the USPTO pursuant to 37 CFR 1.97(b)(1).

Pursuant to 37 CFR 1.98 (d)(1), copies of the references on the PTO/SB/08 are not required to be provided herewith since a copy of each reference was either submitted in an information disclosure statement or cited by the Office in connection with U.S. Serial No. 09/012846 filed January 23, 1998, of which this application claims priority under 35 USC§120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information

9365271_1.DOC

BEST AVAILABLE COPY

as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. JJJ-P02-510. A duplicate copy of this paper is enclosed.

Dated: February 9, 2004

Respectfully submitted,

By Ignacio Perez de la Cruz

Ignacio Perez de la Cruz

Registration No.: P55,535

ROPES & GRAY LLP

45 Rockefeller Plaza

New York, NY 10111-0087

(212) 497-3613

(212) 497-3650 (Fax)

Attorneys/Agents For Applicant



Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	JJJ-P02-510
-------	---	----	---	------------------------	-------------

Complete if Known

Application Number	10/734472
Filing Date	December 12, 2003
First Named Inventor	Marc F. Charette
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	JJJ-P02-510

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-5,652,118	7/29/1997	Ozkaynak et al.	
	AB	US-6,506,729	01-2003	Rueger et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO 94/03200	2/17/1994	Creative Biomolecules, Inc.		
	BB	WO 95/05846	3/2/1995	Genetics Institute, Inc.		
	BC	WO 99/12560-A1	3/18/1999	Creative Biomolecules, Inc.		
	BD	WO 99/21574-A2	5/6/1999	Creative Biomolecules, Inc.		
	BE	WO 97/34626	9/25/1997	Creative Biomolecules, Inc.		
	BF	WO 95/06656	3/9/1995	Harland et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	PERIDES, et al., "Regulation of Neural Cell Adhesion Molecule and L1 by the Transforming Growth Factor- β Superfamily", <i>The Journal of Biological Chemistry</i> , 269:765-770 (1994).	
	CB	LEIN, et al., "Osteogenic Protein-1 Induces Dendritic Growth in Rat Sympathetic Neurons", <i>Neuron</i> , 15:597-605 (1995).	
	CC	BUNSEY, et al., "Selective Damage to the Hippocampal Region Blocks Long-Term Retention of a Natural and Nonspatial Stimulus-Stimulus Association", <i>Hippocampus</i> , 5:546-556 (1995).	
	CD	BUNSEY, et al., "Conservative of hippocampal memory function in rats and humans", <i>Nature</i> , 379:255-257 (1996).	
	CE	KELLOKUMPU-LEHTINEN et al., "Osteogenic Protein-1 (BMP-7), a Novel Bone Morphogenetic Protein", <i>Bone Morphogenetic Proteins: Biology, Biochemistry and Reconstructive Surgery</i> (1996).	
	CF	ARKELL et al., "BMP-7 Influences pattern and growth of the developing hindbrain of mouse embryos", <i>Development</i> 124:1-12 (1997)	
	CG	FURUTA, et al., "Bone morphogenetic proteins (BMPs) as regulators of dorsal forebrain development", <i>Development</i> , 124:2203-2212 (1997).	
	CH	MEHLER, et al., "Bone morphogenetic proteins in the nervous system", <i>Trends Neurosci</i> , 20:309-317 (1997).	
	CI	BISHOP, B., <i>Physical Therapy</i> , Sept. 1982, 62(9):1275-82.	
	CJ	BAHR, B., <i>J. of Neurosci. Res.</i> , October 15, 1985, 42(3):294-305.	
	CK	WOZNEY et al., <i>Science</i> , 242:1528-34, 1988.	
	CL	ZHENG et al., <i>Path. Res. And Practice</i> , 188(8):1104-21, 1992.	
	CM	SKOLNICK et al., <i>Trends in Biotech</i> , 18(1):34-39, 2000.	

Examiner Signature	Date Considered
--------------------	-----------------

9362435_1.DOC

BEST AVAILABLE COPY



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/734472
				Filing Date	December 12, 2003
				First Named Inventor	Marc F. Charette
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	JJJ-P02-510

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CN	WITHERS, et al., <i>Soc. Neurosci. Abstr.</i> , 1996.		
	CO	WILSON et al., <i>Nature</i> , 376:331-333, 1995.		
	CP	VARLEY et al., <i>Dev. Dynamics</i> , 203:434-447, 1995.		
	CQ	SMITH. <i>Elem. Of Molec. Neurobio.</i> , 2 nd ed., p. 141-142, 437, 1996.		
	CR	LAZAR, <i>Mol. Cell Bio.</i> , 8:1247-1252, 1988.		
	CS	BURGESS et al., <i>J. Cell Bio.</i> , 111:2129-2138, 1990.		
	CT	JACKOWSKI, <i>Brit. J. Neurosurg.</i> , 9:303-317, 1995.		
	CU	GUO et al., <i>Brain Res. Devel. Br. Res.</i> , 1997, 104(1-2):101-110.		
	CV	TOMIZAWA et al., <i>Br. Res. Mol. Br. Res.</i> , 1995, 28(1):122-28.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

9362435_1.DOC

BEST AVAILABLE COPY